Skip to main content
PMC home page
Molecular Therapy. Nucleic Acids logoLink to Molecular Therapy. Nucleic Acids
. 2022 Oct 6;30:173. doi: 10.1016/j.omtn.2022.09.021

HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing

Nan Liu, Lifang Zhou, Guifeng Lin, Yun Hu, Yaoge Jiao, Yanhong Wang, Jingming Liu, Shengyong Yang ∗∗, Shaohua Yao ∗
PMCID: PMC9547179  PMID: 36250209

Main text

(Molecular Therapy: Nucleic Acids 29, 36–46; September 2022)

In the originally published version of this article, a statement of the co-first authorship was missed; Nan Liu, Lifang Zhou, and Guifeng Lin contributed equally to this work. This has been corrected online, and the authors regret this error.

Contributor Information

Shengyong Yang, Email: yangsy@scu.edu.cn.

Shaohua Yao, Email: shaohuayao@scu.edu.cn.

Articles from Molecular Therapy. Nucleic Acids are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES